Skip to main content
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
Lyrea avatar

Not yet reviewed — this article is pending editorial review by Lyrea.

JWH-018

JWH-018 molecule structureJWH-018 molecule structure
1-Pentyl-3-(1-naphthoyl)indole
AM-678, Spice (component)
Psychoactive Class

JWH-018 is a synthetic cannabinoid of the naphthoylindole class.1 It gained widespread recognition from 2006 onward as the primary active ingredient in "Spice" brand herbal smoking blends, which were marketed as potpourri and labeled "not for human consumption." The Spice brand became so dominant that the name was eventually adopted as a generic term for all synthetic cannabinoids. JWH-018 produces cannabis-like effects when smoked but carries the heightened risks characteristic of synthetic cannabinoid compounds.

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Light1-2 mg
Moderate2+ mg

Dosing information for smoked JWH-018 derives primarily from oral administration reports and animal research rather than controlled human inhalation studies. Threshold effects have been observed at sub-milligram quantities, though an exact threshold dose has not been determined in published literature. As with other synthetic cannabinoids, considerable variation in potency has been documented across different batches and synthesis methods.

Duration

Onset30 seconds
Total2 hours
Half-life
~1.69 hours (median)

Subjective Effects

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

Effects vary widely by individual, dose, and context.

Physical

Perception of increased weight or Perception of decreased weight

Cognitive

Visual

Auditory

Forked from Subjective Effect Documentation work byJosie Kins September 2015.

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Marquis(MQ)
white → yellow2 → brown2
Mecke(ME)
white → yellow2 → brown2
Mandelin(MD)
yellow2 → black3
Liebermann(LB)
white → yellow2
Powered by PROtestkit.eu

Pharmacology

Pharmacodynamics

JWH-018 acts as a full agonist at both the CB1 and CB2 cannabinoid receptors, with some selectivity for CB2.citation needed It displays binding affinities of 9.00 ± 5.00 nM at CB1 and 2.94 ± 2.65 nM at CB2, with its CB1 affinity reported as approximately five times greater than that of THC. Unlike THC, which acts as a partial agonist at CB1, JWH-018's full agonist activity produces more complete receptor activation.

Pharmacokinetics

JWH-018 undergoes extensive metabolism primarily through hydroxylation and N-dealkylation.citation needed In humans, metabolism occurs mainly on the indole ring and pentyl side chain, with the resulting hydroxylated metabolites undergoing extensive glucuronide conjugation.2 The parent compound and its N-dealkylated metabolite are detected only in small quantities in urine, while hydroxylated N-dealkylated metabolites constitute the primary urinary signal.citation needed When inhaled, the median elimination half-life is approximately 1.69 hours.

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Full Tolerance
Tolerance develops with repeated use, involving CB1 receptor desensitization. Animal studies demonstrate that chronic administration leads to significant downregulation of CB1 receptor function.
Cross Tolerance

Cannabinoids (including THC and other synthetic cannabinoid receptor agonists)

Harm Potential

Addiction & Dependence

Psychological

Moderate

At least one case of JWH-018 dependence has been reported following daily use over eight months.citation needed As a full CB1 agonist with indirect dopaminergic activity, JWH-018 may have greater reinforcing potential than cannabis, though individual susceptibility varies.

Physical

Low

Withdrawal symptoms have been reported following prolonged daily use and were described as more severe than those experienced from cannabis dependence.citation needed

Psychosis Risk

May cause intense anxiety and agitation. Psychotic relapses and anxiety symptoms have been reported in patients with pre-existing mental illness following inhalation.3 Due to concerns about psychosis induction in vulnerable individuals, it is recommended that people with risk factors for psychotic disorders, such as a past or family history of psychosis, not use synthetic cannabinoids.citation needed

Seizure Risk

Seizures and convulsions have been reported in rare cases, though causation has not been definitively established.citation needed

History & Culture

Synthesis

JWH-018 was synthesized by John W. Huffman, an organic chemist at Clemson University,4 as part of his research into compounds affecting the endocannabinoid system. The compound's designation derives from Huffman's initials.5

Legality

By Country

Illegal13
United States flagUnited StatesIllegal
Austria flagAustriaIllegal
Canada flagCanadaIllegal
Denmark flagDenmarkIllegal
Finland flagFinlandIllegal
Germany flagGermanyIllegal
Netherlands flagNetherlandsIllegal
Norway flagNorwayIllegal
Poland flagPolandIllegal
Singapore flagSingaporeIllegal
Sweden flagSwedenIllegal
Ukraine flagUkraineIllegal
United Kingdom flagUnited KingdomIllegal
Controlled / restricted1
Thailand flagThailandRestricted

References

Source Pages

  1. Drug Users Bible by Dominic Milton Trott
  2. PsychonautWiki: JWH-018
  3. Wikipedia

Citations

  1. Liana Fattore, & Walter Fratta. (2011). Beyond THC: The New Generation of Cannabinoid Designer Drugs. https://doi.org/10.3389/fnbeh.2011.000601
  2. Tim Sobolevsky, Ilya Prasolov, & Grigory Rodchenkov. (July 2010). Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Science International, 200(1–3), 141–7. https://doi.org/10.1016/j.forsciint.2010.04.0031
  3. Susanna Every-Palmer. (September 2011). Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug and Alcohol Dependence, 117(2–3), 152–157. https://doi.org/10.1016/j.drugalcdep.2011.01.0121
  4. Huffman, John W.. (2005). Synthesis of Cannabinoid Receptor Ligands — NIH NIDA grant K05-DA015340. National Institute on Drug Abuse / Grantome. https://grantome.com/grant/NIH/K05-DA015340-031
  5. The Unlikely Clemson Chemist Behind Synthetic Marijuana. (n.d.). https://www.wfae.org/local-news/2011-01-25/the-unlikely-clemson-chemist-behind-synthetic-marijuana1
  6. Suchtgiftverordnung. ris.bka.gv.at (n.d.). https://ris.bka.gv.at/NormDokument.wxe?Abfrage=Bundesnormen&Anlage=4&Artikel=&Gesetzesnummer=10011053&Paragraf=&ShowPrintPreview=True&Uebergangsrecht=1
  7. Controlled Drugs and Substances Act. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/acts/C-38.8/FullText.html1
  8. Bekendtgørelse om euforiserende stoffer (BEK nr 405 af 26/03/2026), liste B. retsinformation.dk (n.d.). https://www.retsinformation.dk/api/pdf/2559321
  9. Valtioneuvoston asetus huumausaineina pidettävistä aineista, valmisteista ja kasveista (543/2008). finlex.fi (n.d.). https://www.finlex.fi/fi/lainsaadanto/2008/5431
  10. Betäubungsmittelgesetz. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/btmg_1981/anlage_ii.html1

Further Reading

  1. Brents et al. (2011) - Phase I Metabolites Activity
  2. CYP2C9 polymorphism metabolism
  3. Freeman et al. (2013) - Stroke Association
  4. Grigoryev et al. (2022) - Psychotomimetic Effects Study
  5. Human Inhalation Pharmacokinetics (2–3 mg)
  6. Human inhalation PK (2–3 mg)
  7. JWH-018 Phase 1 Pilot Study
  8. Koller et al. (2022) - Cannabinoid-Induced Seizures
  9. Phase-1 pilot, 2 & 3 mg inhaled
  10. Psychotomimetic 5.5 mg study
  11. Rat tolerance & CB1 desensitisation
  12. Rat Tolerance and CB1 Desensitization
  13. Schneir et al. (2011) - Synthetic Cannabinoid Intoxication
  14. Severe toxicity with seizures

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed — this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes8 human edits · latest

Times are UTCNewest first

26 August 2026

  1. Lyrea · Edited in History & CultureSections 2 › Content

24 January 2026

  1. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  2. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  3. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  4. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  5. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  6. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  7. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the JWH-018 article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.